Recruitment

Recruitment Status
Terminated
Estimated Enrollment
115

Summary

Conditions
Retinal Vein Occlusion
Type
Observational
Design
  • Observational Model: Cohort
  • Time Perspective: Prospective

Participation Requirements

Min Age
18
Max Age
99
Gender
Both

Description

People treated with ranibizumab for edema due to retinal vein occlusion as part of previous studies at the Wilmer Eye Institute and who are currently being seen by their ophthalmologist at the Wilmer Eye Institute are followed up to assess long term outcomes

People treated with ranibizumab for edema due to retinal vein occlusion as part of previous studies at the Wilmer Eye Institute and who are currently being seen by their ophthalmologist at the Wilmer Eye Institute are followed up to assess long term outcomes

Locations

Baltimore, Maryland, 21287
Baltimore, Maryland, 21287

Tracking Information

NCT #
NCT01875770
Collaborators
Not Provided
Investigators
  • Principal Investigator: Peter Campochiaro, MD Johns Hopkins University
  • Peter Campochiaro, MD Johns Hopkins University